Genome-wide Programmable Transcriptional Memory by CRISPR-based Epigenome Editing
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA705864 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR13823912.fastq.gz | Fastqsanger.gz | |||
| SRR13823913.fastq.gz | Fastqsanger.gz | |||
| SRR13823914.fastq.gz | Fastqsanger.gz | |||
| SRR13823915.fastq.gz | Fastqsanger.gz | |||
| SRR13823916.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 90 |
Similar Datasets
Project description:General approaches for heritably altering gene expression would enable many discovery and therapeutic efforts. Here, we present CRISPRoff— a programmable epigenetic memory writer consisting of a single dead Cas9 fusion protein that establishes DNA methylation and repressive histone modifications. Transient CRISPRoff expression initiates highly specific DNA methylation and gene repression that is maintained through cell division and differentiation of stem cells to neurons. Pairing CRISPRoff with genome-wide screens and analysis of chromatin marks enabled us to explore the rules for heritable silencing. We identify sgRNAs capable of silencing the large majority of genes including those lacking canonical CpG islands (CGIs) and reveal a wide targeting window extending beyond annotated CGIs. Our finding that targeted DNA methylation outside of CGIs leads to memorized gene silencing expands the canonical model of methylation-based silencing and broadly enables diverse applications including genome-wide screens, multiplexed cell engineering, enhancer silencing, and mechanistic exploration of epigenetic inheritance.
2021-04-12 | GSE168012 | GEO
Project description:A general approach for heritably altering gene expression has the potential to enable many discovery and therapeutic efforts. Here, we present CRISPRoff-a programmable epigenetic memory writer consisting of a single dead Cas9 fusion protein that establishes DNA methylation and repressive histone modifications. Transient CRISPRoff expression initiates highly specific DNA methylation and gene repression that is maintained through cell division and differentiation of stem cells to neurons. Pairing CRISPRoff with genome-wide screens and analysis of chromatin marks establishes rules for heritable gene silencing. We identify single guide RNAs (sgRNAs) capable of silencing the large majority of genes including those lacking canonical CpG islands (CGIs) and reveal a wide targeting window extending beyond annotated CGIs. The broad ability of CRISPRoff to initiate heritable gene silencing even outside of CGIs expands the canonical model of methylation-based silencing and enables diverse applications including genome-wide screens, multiplexed cell engineering, enhancer silencing, and mechanistic exploration of epigenetic inheritance.
| S-EPMC8376083 | biostudies-literature
Project description:Precisely engineering histone acylation states can inform mechanistic epigenetics and catalyze new therapeutic epigenome editing opportunities. Here, we developed engineered lysine acyltransferases that enable the deposition of acetylation and longer-chain acylations in a programmable manner using a dead Cas9 (dCas9) fusion protein. We show that targeting an engineered lysine crotonyltransferase, developed by mutagenizing the native human p300 protein, results in relatively weak levels of endogenous enhancer activation yet retains strong potency when targeted to promoters. We further identify a single mutation within the catalytic core of human p300 that preserves enzymatic activity while promoting more target-specific acetylation and substantially reducing downstream transcriptomic perturbations. Further, this novel fusion protein exhibits low cytotoxicity but maintains high levels of H3K27ac deposition, enabling markedly improved lentiviral delivery. We leveraged this enhanced delivery and improved cytotoxicity profile to perform single-cell CRISPR activation screening. Using proteomics and a panel of engineered p300 variants, we also discover acylation-specific interactions and link the cytotoxicity of the wild-type p300 core domain to altered activities among DNA repair machinery components. These new programable epigenome editing tools and insights expand our ability to perform functional genomic screens, multiplexed cell engineering, and, more broadly, understand the mechanistic role of lysine acylation in epigenetic and cellular processes.
2026-02-06 | GSE255561 | GEO
Project description:Precisely engineering histone acylation states can inform mechanistic epigenetics and catalyze new therapeutic epigenome editing opportunities. Here, we developed engineered lysine acyltransferases that enable the deposition of acetylation and longer-chain acylations in a programmable manner using a dead Cas9 (dCas9) fusion protein. We show that targeting an engineered lysine crotonyltransferase, developed by mutagenizing the native human p300 protein, results in relatively weak levels of endogenous enhancer activation yet retains strong potency when targeted to promoters. We further identify a single mutation within the catalytic core of human p300 that preserves enzymatic activity while promoting more target-specific acetylation and substantially reducing downstream transcriptomic perturbations. Further, this novel fusion protein exhibits low cytotoxicity but maintains high levels of H3K27ac deposition, enabling markedly improved lentiviral delivery. We leveraged this enhanced delivery and improved cytotoxicity profile to perform single-cell CRISPR activation screening. Using proteomics and a panel of engineered p300 variants, we also discover acylation-specific interactions and link the cytotoxicity of the wild-type p300 core domain to altered activities among DNA repair machinery components. These new programable epigenome editing tools and insights expand our ability to perform functional genomic screens, multiplexed cell engineering, and, more broadly, understand the mechanistic role of lysine acylation in epigenetic and cellular processes.
2026-02-06 | GSE255194 | GEO
Project description:Precisely engineering histone acylation states can inform mechanistic epigenetics and catalyze new therapeutic epigenome editing opportunities. Here, we developed engineered lysine acyltransferases that enable the deposition of acetylation and longer-chain acylations in a programmable manner using a dead Cas9 (dCas9) fusion protein. We show that targeting an engineered lysine crotonyltransferase, developed by mutagenizing the native human p300 protein, results in relatively weak levels of endogenous enhancer activation yet retains strong potency when targeted to promoters. We further identify a single mutation within the catalytic core of human p300 that preserves enzymatic activity while promoting more target-specific acetylation and substantially reducing downstream transcriptomic perturbations. Further, this novel fusion protein exhibits low cytotoxicity but maintains high levels of H3K27ac deposition, enabling markedly improved lentiviral delivery. We leveraged this enhanced delivery and improved cytotoxicity profile to perform single-cell CRISPR activation screening. Using proteomics and a panel of engineered p300 variants, we also discover acylation-specific interactions and link the cytotoxicity of the wild-type p300 core domain to altered activities among DNA repair machinery components. These new programable epigenome editing tools and insights expand our ability to perform functional genomic screens, multiplexed cell engineering, and, more broadly, understand the mechanistic role of lysine acylation in epigenetic and cellular processes.
2025-11-11 | GSE255608 | GEO
Project description:Precisely engineering histone acylation states can inform mechanistic epigenetics and catalyze new therapeutic epigenome editing opportunities. Here, we developed engineered lysine acyltransferases that enable the deposition of acetylation and longer-chain acylations in a programmable manner using a dead Cas9 (dCas9) fusion protein. We show that targeting an engineered lysine crotonyltransferase, developed by mutagenizing the native human p300 protein, results in relatively weak levels of endogenous enhancer activation yet retains strong potency when targeted to promoters. We further identify a single mutation within the catalytic core of human p300 that preserves enzymatic activity while promoting more target-specific acetylation and substantially reducing downstream transcriptomic perturbations. Further, this novel fusion protein exhibits low cytotoxicity but maintains high levels of H3K27ac deposition, enabling markedly improved lentiviral delivery. We leveraged this enhanced delivery and improved cytotoxicity profile to perform single-cell CRISPR activation screening. Using proteomics and a panel of engineered p300 variants, we also discover acylation-specific interactions and link the cytotoxicity of the wild-type p300 core domain to altered activities among DNA repair machinery components. These new programable epigenome editing tools and insights expand our ability to perform functional genomic screens, multiplexed cell engineering, and, more broadly, understand the mechanistic role of lysine acylation in epigenetic and cellular processes.
2026-02-06 | GSE289257 | GEO
Project description:Precisely engineering histone acylation states can inform mechanistic epigenetics and catalyze new therapeutic epigenome editing opportunities. Here, we developed engineered lysine acyltransferases that enable the deposition of acetylation and longer-chain acylations in a programmable manner using a dead Cas9 (dCas9) fusion protein. We show that targeting an engineered lysine crotonyltransferase, developed by mutagenizing the native human p300 protein, results in relatively weak levels of endogenous enhancer activation yet retains strong potency when targeted to promoters. We further identify a single mutation within the catalytic core of human p300 that preserves enzymatic activity while promoting more target-specific acetylation and substantially reducing downstream transcriptomic perturbations. Further, this novel fusion protein exhibits low cytotoxicity but maintains high levels of H3K27ac deposition, enabling markedly improved lentiviral delivery. We leveraged this enhanced delivery and improved cytotoxicity profile to perform single-cell CRISPR activation screening. Using proteomics and a panel of engineered p300 variants, we also discover acylation-specific interactions and link the cytotoxicity of the wild-type p300 core domain to altered activities among DNA repair machinery components. These new programable epigenome editing tools and insights expand our ability to perform functional genomic screens, multiplexed cell engineering, and, more broadly, understand the mechanistic role of lysine acylation in epigenetic and cellular processes.
2026-02-06 | GSE255195 | GEO
Project description:Precisely engineering histone acylation states can inform mechanistic epigenetics and catalyze new therapeutic epigenome editing opportunities. Here, we developed engineered lysine acyltransferases that enable the deposition of acetylation and longer-chain acylations in a programmable manner using a dead Cas9 (dCas9) fusion protein. We show that targeting an engineered lysine crotonyltransferase, developed by mutagenizing the native human p300 protein, results in relatively weak levels of endogenous enhancer activation yet retains strong potency when targeted to promoters. We further identify a single mutation within the catalytic core of human p300 that preserves enzymatic activity while promoting more target-specific acetylation and substantially reducing downstream transcriptomic perturbations. Further, this novel fusion protein exhibits low cytotoxicity but maintains high levels of H3K27ac deposition, enabling markedly improved lentiviral delivery. We leveraged this enhanced delivery and improved cytotoxicity profile to perform single-cell CRISPR activation screening. Using proteomics and a panel of engineered p300 variants, we also discover acylation-specific interactions and link the cytotoxicity of the wild-type p300 core domain to altered activities among DNA repair machinery components. These new programable epigenome editing tools and insights expand our ability to perform functional genomic screens, multiplexed cell engineering, and, more broadly, understand the mechanistic role of lysine acylation in epigenetic and cellular processes.
2026-02-06 | GSE289920 | GEO
Project description:Epigenetic aberration is one of the major driving factors in human cancer, often leading to acquired resistance to chemotherapies. Various chemical epigenetic modulators have been reported. Nonetheless, outcomes from animal models and clinical trials have underscored the substantial setbacks attributed to pronounced on- and off-target toxicities. To address these challenges, CRISPR/dCas9 technology emerges as a potent tool for precise epigenetic regulation. This relies on the co-expression of exogenous epigenetic modulator proteins, presenting technical challenges during preparation and delivery, as well as potential undesirable side effects. Recently, our research demonstrated that Cas9 tagged with the FCPF-peptide motif could be recognized by perfluoro biphenyl (PFB) derivatives. Here, we integrated the FCPF-tag into dCas9 and established a chemically inducible platform for epigenome editing, called Chem-CRISPR/dCas9FCPF. We designed a series of chemical inhibitor-PFB conjugates targeting various epigenetic modulator proteins. Focusing on JQ1, a BRD4 inhibitor, we demonstrate that c-MYC-sgRNA-guided JQ1-PFB specifically inhibits BRD4 in close proximity to the c-MYC promoter/enhancer, thereby effectively repressing the intricate transcription networks orchestrated by c-MYC. In conclusion, our Chem-CRISPR/dCas9FCPF platform presents a promising alternative to conventional fusion protein systems. It replaces exogenous epigenetic modulator proteins with chemical inhibitors, offering a highly efficient and precise approach to epigenome editing.
2025-05-06 | PXD048673 | Pride
Project description:N6-methyladenonsine (m6A) is the most prevalent modification on mRNA and plays critical roles in mRNA processing and metabolism. However, how the m6A modification on individual gene of interest regulates gene function and the links to phenotypic outcome in plants are mostly unknown. Here, we described the construction and characterization of programmable m6A editing tools by fusing the m6A writer, core catalytical domain of MTA and MTB complex, and eraser, ALKBH5, to catalytically dead Cas13a (dCas13a), respectively, for targeting methylation and demethylation of specific mRNA. We demonstrated that our m6A editors could efficiently and specifically add and remove the m6A modification on specific RNA transcript in both Nicotiana benthamiana and Arabidopsis. Moreover, targeting SHORT-ROOT (SHR) transcript with methylation editor could significantly increase its m6A levels with limited off-target effects and enhance its expression, giving rise to induced plant growth with enlarged leaf size and root, increased plant height, plant biomass and total grain weight in Arabidopsis. Collectively, these findings suggest that our programmable m6A editing tools can be applied to study m6A modification of specific genes in plants, and might also have great potential applications for crop improvement in future
2024-01-01 | GSE221143 | GEO